Navigation Links
Large-Scale Survey Reveals Low Sexual Desire Most Common Distressing Female Sexual Problem, Affecting Up to One in 10 Women
Date:10/31/2008

RIDGEFIELD, Conn., Oct. 31 /PRNewswire/ -- Results from PRESIDE (Prevalence of Female Sexual Problems Associated with Distress and Determinants of Treatment Seeking), the largest survey assessing the prevalence of female sexual problems, show that low sexual desire is the most commonly reported sexual problem in women age 18 or older. In this new national survey of more than 31,000 women in the United States, published today in Obstetrics & Gynecology (the Green Journal), nearly one in 10 women reported low desire with sexually-related personal distress, a problem that can be a primary medical condition known as Hypoactive Sexual Desire Disorder (HSDD) or secondary to other chronic medical conditions (e.g., depression, thyroid conditions) or medication use. Participants in this survey were not clinically evaluated by a healthcare professional to determine the underlying causes of the reported sexual problems.

HSDD remains largely under-diagnosed in the United States. The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, defines HSDD as the persistent lack (or absence) of sexual fantasies or desire for any form of sexual activity marked by distress or interpersonal difficulty and not better accounted for by another disorder (except another sexual dysfunction), direct physiological effects of a substance (including medications) or a general medical condition.

"Physicians who diagnose and treat women with sexual problems should also make sure to evaluate the patient's level of distress associated with her problem," said Jan L. Shifren, M.D., lead author of the study and director, Menopause Program, Vincent Obstetrics and Gynecology Service at Massachusetts General Hospital, Boston. "As distressing sexual problems were identified in approximately one in eight women, healthcare providers need to ask their patients about sexual concerns, and whether they are causing unhappiness, frustration or other distressing feelings that may be impacting their quality of life."

PRESIDE Results

In the PRESIDE survey, 44.2 percent of women reported experiencing any sexual problem. Low desire was most common, reported in 38.7 percent of all respondents; low arousal (26.1%) and orgasm difficulty (20.5%) were less frequent. Of all the women surveyed, 22.8 percent said they had sexually-related personal distress.

One in eight women (12%) said they had either low desire, low arousal or orgasm difficulty plus personal distress, meaning that, for example, the sexual issue caused the woman to feel frustrated, stressed, angry, embarrassed or unhappy. Low desire was the most common distressing sexual problem, affecting 10 percent of respondents, followed by arousal plus distress (5.4%) and orgasm difficulty plus distress (4.7%). Younger women (ages 18-44; 10.8%) and middle-aged women (45-64; 14.8%) were more likely to suffer a distressing sexual problem than older women (65+; 8.9%). In addition, these women tended to have poor self-assessed health and a low level of education as well as other health issues such as depression, anxiety, thyroid conditions and urinary incontinence.

About PRESIDE

PRESIDE is a cross-sectional, population-based, nationally-representative survey of 31,581 adult women in the United States.

As female sexual dysfunction is characterized by sexual problems associated with personal distress, two validated instruments were used. The Changes in Sexual Functioning Questionnaire (CSFQ-14), a 14-item validated tool, was used to capture a respondent's self-evaluation of current sexual behaviors and problems using a five-point scale. The Female Sexual Distress Scale (FSDS), a 12-item validated tool, measures a woman's distress about her sex life, assesses guilt, frustration, stress, worry, anger, embarrassment and unhappiness during the past 30 days.

Funding for PRESIDE was provided by Boehringer Ingelheim.

Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and approximately 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of US $15.0 billion (10.9 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information, please visit http://us.boehringer-ingelheim.com.


'/>"/>
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Illinois Meth Project Launches Large-Scale Meth Prevention Campaign
2. NIH report on intracranial stent points out need for upcoming large-scale clinical trial
3. Survey reveals disparities in skin cancer knowledge, protection among high school students
4. New Survey Shows Americans are Still Concerned About Food Safety, Yet Still Not Smart About What They Like to Eat
5. One of the Largest Post-WHI Physician Surveys Shows More Education is Needed: Patient Misinformation About Hormone Therapy Remains High
6. Hospitals Could Improve Outcomes for Patients and Save Millions According to Hill-Rom 10th Annual Pressure Ulcer Survey
7. Youth Drug Use at a Five Year Low, New Survey Shows
8. Survey From The Partnership and MetLife Foundation Reveals Important Role Todays Grandparents Play in Teens Lives
9. Parental surveys boost diagnosis abilities of pediatricians
10. National Survey Shows Employee Fears About Consumer-Driven Health Plans on Decline
11. JHA Releases 2007 U.S. Group Disability Mid-Year Market Survey Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 2016 , ... This campaign aims to provide a path to improved education ... control and change. , As nearly 795,000 Americans suffering from a new or recurrent ... Plus, with an estimated 129,000 of these people dying from stroke, it’s become our ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees ... stories, courtesy of leaders in the nursing and health care industry. It also ... advocates and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning is ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports ... Yellen and company to wait until March 2017 for an interest rate increase, according ... Robinson College of Business. , “The Federal Open Market Committee (FOMC) dot charts are ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... and clinical outcomes, hosted members and suppliers for its inaugural Member Conference at ... on their mission of elevating the operational health of America’s healthcare providers. , ...
(Date:5/26/2016)... Florida (PRWEB) , ... May 26, 2016 , ... ... House® Project offering a new model of care for living and healing, celebrated ... core values: Meaningful Life in a Real Home provided by Empowered Staff. , “This ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... Amarantus BioScience Holdings, Inc. ... Regenerative Medicine, Neurology and Orphan Diseases, today announced that President & ... upcoming investor conferences: SeeThru Equity MicroCap Conference   ... New York City , NY When: Tuesday, May ... Conference   Where: Grand Hyatt Hotel, 109 East 42 ...
(Date:5/26/2016)... NASHVILLE, Tenn. , May 26, 2016 ... provider of software and analytics, network solutions ... healthcare, today announced it entered into a ... leading provider of outpatient software solutions and ... surgery centers, specialty hospitals and rehabilitation clinics ...
(Date:5/25/2016)... , Germany and GERMANTOWN, ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... licensing and co-development agreement with Therawis Diagnostics GmbH to develop ... be to develop and market PITX2 as a marker to ... high-risk breast cancer patients. "We are pleased to ...
Breaking Medicine Technology: